How can I receive help paying for HALAVEN®?
HALAVEN $0 Co-Pay Program*
Learn if you are eligible for the HALAVEN $0 Co-Pay Program, which may be able to help you with the out-of-pocket costs of HALAVEN.
The Eisai Assistance Program
Eisai, the maker of HALAVEN, believes that cost should not be a barrier to receiving treatment. That’s why we’re committed to helping you identify what financial support may be available to you. We offer the Eisai Assistance Program (EAP). This program offers insurance information and financial support to eligible patients and caregivers for Eisai products and medicines, although Eisai cannot guarantee coverage.
*The HALAVEN $0 Co-Pay Program assists eligible patients with the out-of -pocket costs of HALAVEN (up to $18,000 per year). Restrictions apply. Visit www.eisaireimbursement.com/patient/halaven to see the full terms and conditions and eligibility requirements, to learn more about the program, and to download an enrollment form. Eligible commercially insured patients may pay as little as $0 per month, with an annual limit of $18,000. See www.eisaireimbursement.com/patient/halaven for complete eligibility requirements and terms and conditions.
The EAP can help you
- Understand how your therapy may be covered by your insurance
- Understand your out-of-pocket cost, which is the part you pay for and can include co-pays, co-insurance, or deductibles
- Identify sources of potential coverage if you do not have insurance, including eligibility for the Eisai Patient Assistance Program (PAP)
Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims.
Restrictions apply. Visit www.eisaireimbursement.com/patient/halaven to see the full terms and conditions, eligibility requirements, to learn more about the program, and download an enrollment form.
To learn more about the HALAVEN $0 Co-Pay Program and the PAP for HALAVEN
- Call 1.866.61.EISAI (1.866.613.4724)
Monday–Friday, 9 AM to 6 PM, ET - Click to visit www.eisaireimbursement.com/patient/halaven
Who is HALAVEN (eribulin mesylate) Injection for?
HALAVEN is a prescription medicine used to treat adults with breast cancer that has spread to other parts of the body, and who have already received other types of anticancer medicines after the cancer has spread.
What safety information do I need to know about HALAVEN?
HALAVEN can cause serious side effects, including
- Low white blood cell count (neutropenia). This can lead to serious infections that could lead to death. Your health care provider will check your blood cell counts. Call your health care provider right away if you develop fever (temperature above 100.5°F), chills, cough, or burning or pain when you urinate, as any of these can be symptoms of infection
- Numbness, tingling, or pain in your hands or feet (peripheral neuropathy). Peripheral neuropathy is common with HALAVEN and sometimes can be severe. Tell your health care provider if you have new or worsening symptoms of peripheral neuropathy
- Your health care provider may delay or decrease your dose or stop treatment with HALAVEN if you have side effects
Before you receive HALAVEN, tell your health care provider about all of your medical conditions, including if you
- have liver or kidney problems
- have heart problems, including a problem called congenital long QT syndrome
- have low potassium or low magnesium in your blood
- are pregnant or plan to become pregnant. HALAVEN can harm your unborn baby. Tell your health care provider right away if you become pregnant or think you are pregnant during treatment with HALAVEN. Females who are able to become pregnant should use an effective form of birth control during treatment with HALAVEN and for at least 2 weeks after the final dose of HALAVEN and males should use an effective form of birth control when having sex with female partners who are able to become pregnant during treatment with HALAVEN and for 3½ months (14 weeks) after the final dose of HALAVEN
- are breastfeeding or plan to breastfeed. It is not known if HALAVEN passes into your breast milk. Do not breastfeed during treatment with HALAVEN and for 2 weeks after the final dose of HALAVEN
Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of HALAVEN?
HALAVEN can cause changes in your heartbeat (called QT prolongation). This can cause irregular heartbeats. Your health care provider may do heart monitoring (electrocardiogram or ECG) or blood tests during your treatment with HALAVEN to check for heart problems.
The most common side effects of HALAVEN in adults with breast cancer include low white blood cell count (neutropenia), low red blood cell count (anemia), weakness or tiredness, hair loss (alopecia), nausea, and constipation.
Your health care provider will do blood tests before and during treatment while you are taking HALAVEN.
For more information about HALAVEN, please see full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.